Uncategorized

IRLAB Signs Phase III Regulatory US Consultants to Support Preparation for Mesdopetam’s end-of-Phase 2 Meeting with the US FDA

IRLAB Therapeutics IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company has secured top expertise in supporting the preparations for Phase III with mesdopetam.

IRLAB Signs Phase III Regulatory US Consultants to Support Preparation for Mesdopetam’s end-of-Phase 2 Meeting with the US FDA Read More »

Genentech’s Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III Trials

Genentech, a member of the Roche Group, announced positive topline long-term results from the global Phase III BALATON and COMINO studies evaluating extended treatment intervals with Vabysmo® in macular edema due to branch and central retinal vein occlusion.

Genentech’s Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III Trials Read More »

AstriVax Strengthens Leadership Team by Welcoming Chief Development Officer (CDO) Dr. Mathieu Peeters and Chief Financial Officer (CFO) Barbara Freitag

AstriVax is pleased to announce that Dr. Mathieu Peeters and Barbara Freitag have joined the company’s leadership team as Chief Development Officer and Chief Financial Officer, respectively.

AstriVax Strengthens Leadership Team by Welcoming Chief Development Officer (CDO) Dr. Mathieu Peeters and Chief Financial Officer (CFO) Barbara Freitag Read More »

Scroll to Top